TDP1 overexpression in cancer is linked to resistance to topoisomerase I (TOP1)-targeting therapies (Duffy et al., 2016, Liu et al., 2007), and its reduced expression is linked to mutations that cause neurological disease (El-Khamisy et al., 2005, Takashima et al., 2002). This evidence concerns the gene TOP1 and cancer.